ATE445012T1 - Mit rheumatischer arthritis assoziierte spleissvariante von cd44 - Google Patents

Mit rheumatischer arthritis assoziierte spleissvariante von cd44

Info

Publication number
ATE445012T1
ATE445012T1 AT00935449T AT00935449T ATE445012T1 AT E445012 T1 ATE445012 T1 AT E445012T1 AT 00935449 T AT00935449 T AT 00935449T AT 00935449 T AT00935449 T AT 00935449T AT E445012 T1 ATE445012 T1 AT E445012T1
Authority
AT
Austria
Prior art keywords
transcript
found
exon
novel
variant
Prior art date
Application number
AT00935449T
Other languages
English (en)
Inventor
David Naor
Itshak Golan
Shlomo Nedvetzki
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from IL13035699A external-priority patent/IL130356A0/xx
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE445012T1 publication Critical patent/ATE445012T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70585—CD44
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00935449T 1999-06-08 2000-06-07 Mit rheumatischer arthritis assoziierte spleissvariante von cd44 ATE445012T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL13035699A IL130356A0 (en) 1999-06-08 1999-06-08 Novel CD44 variant
IL13364799A IL133647A0 (en) 1999-06-08 1999-12-21 Novel cd44 variant
PCT/IL2000/000326 WO2000075312A1 (en) 1999-06-08 2000-06-07 Cd44 splice variant associated with rheumatoid arthritis

Publications (1)

Publication Number Publication Date
ATE445012T1 true ATE445012T1 (de) 2009-10-15

Family

ID=26323849

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00935449T ATE445012T1 (de) 1999-06-08 2000-06-07 Mit rheumatischer arthritis assoziierte spleissvariante von cd44

Country Status (7)

Country Link
US (1) US20030108984A1 (de)
EP (1) EP1187917B1 (de)
AT (1) ATE445012T1 (de)
AU (1) AU5098800A (de)
DE (1) DE60043104D1 (de)
IL (1) IL133647A0 (de)
WO (1) WO2000075312A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
CA2441206A1 (en) 2001-03-19 2002-09-26 Gyros Ab Characterization of reaction variables
AU2002326112A1 (en) * 2001-08-09 2003-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem Cd44 variants carrying heparan sulfate chains and uses thereof
DE60316106T2 (de) * 2002-01-09 2008-05-29 Faron Pharmaceuticals Oy Gemeinsamer lymphatischer endothel- und gefässendothel-rezeptor-1 (clever-1) und seine verwendung
ATE533788T1 (de) * 2003-07-15 2011-12-15 Yissum Res Dev Co Antikörper gegen cd44vra und methoden zu ihrer verwendung
JP4459179B2 (ja) * 2005-03-30 2010-04-28 株式会社東芝 情報処理装置及びその方法
US20060294607A1 (en) * 2006-03-29 2006-12-28 Applera Corporation Human podocalyxin alternative-spliced forms and uses thereof
WO2009007934A2 (en) * 2007-07-10 2009-01-15 Neurim Pharmaceuticals (1991) Ltd. Cd44 splice variants in neurodegenerative diseases
WO2010058396A1 (en) * 2008-11-19 2010-05-27 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. A cd44vra antibody and diagnostic and therapeutic methods using same
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
WO2024093147A1 (zh) * 2022-10-31 2024-05-10 南京元迈细胞生物科技有限公司 一种特异性结合CD44的v5外显子的抗体及其用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USH735H (en) * 1988-03-30 1990-02-06 The United States Of America As Represented By The United States Department Of Energy Lead-203 as a label for radioimaging
AU5543594A (en) * 1992-10-30 1994-05-24 Duke University An adhesion molecule
CA2164728A1 (en) * 1993-06-22 1995-01-05 Helmut Ponta Processes for diagnosing and analysing tumours
DE19708713C2 (de) * 1997-03-04 2002-11-28 Boehringer Ingelheim Int Verwendung von anti-CD44 Antikörpern enthaltenden Präparationen zur Behandlung bestimmter Tumore und zur Unterdrückung von Immunreaktionen
ATE533788T1 (de) * 2003-07-15 2011-12-15 Yissum Res Dev Co Antikörper gegen cd44vra und methoden zu ihrer verwendung

Also Published As

Publication number Publication date
WO2000075312A1 (en) 2000-12-14
EP1187917A1 (de) 2002-03-20
IL133647A0 (en) 2001-04-30
EP1187917B1 (de) 2009-10-07
DE60043104D1 (de) 2009-11-19
US20030108984A1 (en) 2003-06-12
AU5098800A (en) 2000-12-28

Similar Documents

Publication Publication Date Title
Asl et al. A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis
Baba et al. A novel allelic variant of serum amyloic A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA–amyloidosis
DE60043104D1 (de) Mit rheumatischer arthritis assoziierte spleissvariante von cd44
EP0753580A3 (de) Zellspezifische Gentherapie mit Hilfe eines neuen Promotors für den "Tissue Inhibitor of Metalloproteinase-3"
ATE435281T1 (de) Im cadasil bezogenes gen, diagnostikums-verfahren und therapeutische verwendung
DE60037800D1 (de) Stereoselektive antifibrillogene peptide
DE69728864D1 (de) Direkte molekulare diagnose von friedreich ataxia
ATE389724T1 (de) Menschliche dnase i hyperaktive varianten
WO2004045553A3 (en) Ca125 gene and its use for diagnostic and therapeutic interventions
ATE221125T1 (de) Klonierte glutaminsäure-decarboxylase
IL141021A (en) Use of copolymer-like polypeptide-1 to prepare a drug to treat autoimmune diseases
DK1295944T3 (da) GDP-dissociationsstimulerende protein, hjernespecifikt nukleosomsamlingsprotein, skeletmuskelspecifikt ubiquitinkonjugerende enzym, celleproliferationsprotein, phosphatidylinositolkinase, nelbeslægtede proteiner
BR9607336A (pt) Composições de aminoácidos e utilidades das mesmas em nutrição clinica
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DE69735020D1 (de) Verfahren zur Diagnose von Prostatakrebs
WO1997044454A3 (en) Human phospholipase inhibitor
Peterson et al. Increased spectrin proteolysis in fibroblasts from aged and Alzheimer donors
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
Paepe et al. Homozygosity by descent for a COL1A2 mutation in two sibs with severe osteogenesis imperfecta and mild clinical expression in the heterozygotes
US20040018188A9 (en) Sparc-related proteins
Park et al. Cloning of the genes encoding mouse cardiac and skeletal calsequestrins: expression pattern during embryogenesis
BR9808625A (pt) O uso de proteìnas extraìveis de órgãos de animal para a preparação de medicamentos para o tratamento de condições patológicas caracterizadas por hiperprodução de fator de necrose de tumor (tnf)
Lund et al. Cloning and sequencing of the bovine gastrin gene
Nuytinck et al. Osteogenesis imperfecta phenotypes resulting from serine for glycine substitutions in the α2 (I) collagen chain
ATE218064T1 (de) Immunogene tlp-zusammensetzung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties